Next Article in Journal
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
Previous Article in Journal
Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 14
10.3390/cancers16142587
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cancers 2020, 12(2), 512.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512

by
Mohammad Krayem
1,*,†,
Philippe Aftimos
2,†,
Ahmad Najem
1,
Tim van den Hooven
3,
Adriënne van den Berg
3,
Liesbeth Hovestad-Bijl
3,
Rik de Wijn
3,
Riet Hilhorst
3,
Rob Ruijtenbeek
3,
Malak Sabbah
1,
Joseph Kerger
2,
Ahmad Awada
1,2,
Fabrice Journe
1 and
Ghanem E. Ghanem
1
1
Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium
2
Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium
3
PamGene International BV, 5211HH ‘s-Hertogenbosch, The Netherlands
*
Author to whom correspondence should be addressed.
†
Both authors equally contributed to this manuscript.
Cancers 2024, 16(14), 2587; https://doi.org/10.3390/cancers16142587
Submission received: 7 April 2024 / Accepted: 8 May 2024 / Published: 19 July 2024
Browse Figure
Versions Notes

Error in Figure

In the original article [1], there was a mistake in Figure 3C as published. The ERK, AKT, and SRC blots in our publication in Cancers (Figure 3C) were flipped when resizing the images. Note that this mistake does not change or alter the content and conclusions of our paper. The mistake indeed concerns control experiments, which were reproduced very easily. The corrected Erratum Figure 3C appears below.
The pERK that appears on the third line for the conditions MM074 and MM074-R is correct, and the error came from another paper published in Oncotarget (https://doi.org/10.18632/oncotarget.25879) that was retracted.
In the original article, the first author's name is missing an m, and the correct version is Mohammad Krayem.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Krayem, M.; Aftimos, P.; Najem, A.; van den Hooven, T.; van den Berg, A.; Hovestad-Bijl, L.; de Wijn, R.; Hilhorst, R.; Ruijtenbeek, R.; Sabbah, M.; et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512. [Google Scholar] [CrossRef] [PubMed]
Cancers 16 02587 g003
Figure 3. (C) Western Blot analysis of key targeted protein in MAPK, PI3K/AKT and SRC signalling pathways in four BRAFi sensitive, and six cell lines with intrinsic (MM043 and MM054) and acquired resistance to vemurafenib, (R refers to acquired resistant cells compared to parental sensitive cells).
Figure 3. (C) Western Blot analysis of key targeted protein in MAPK, PI3K/AKT and SRC signalling pathways in four BRAFi sensitive, and six cell lines with intrinsic (MM043 and MM054) and acquired resistance to vemurafenib, (R refers to acquired resistant cells compared to parental sensitive cells).
Cancers 16 02587 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Krayem, M.; Aftimos, P.; Najem, A.; van den Hooven, T.; van den Berg, A.; Hovestad-Bijl, L.; de Wijn, R.; Hilhorst, R.; Ruijtenbeek, R.; Sabbah, M.; et al. Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512. Cancers 2024, 16, 2587. https://doi.org/10.3390/cancers16142587

AMA Style

Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, et al. Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512. Cancers. 2024; 16(14):2587. https://doi.org/10.3390/cancers16142587

Chicago/Turabian Style

Krayem, Mohammad, Philippe Aftimos, Ahmad Najem, Tim van den Hooven, Adriënne van den Berg, Liesbeth Hovestad-Bijl, Rik de Wijn, Riet Hilhorst, Rob Ruijtenbeek, Malak Sabbah, and et al. 2024. "Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512" Cancers 16, no. 14: 2587. https://doi.org/10.3390/cancers16142587

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop